The trial attained both its Main endpoints, with semaglutide 2.4 mg demonstrating statistically substantial and remarkable improvements in liver fibrosis without any worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in individuals with MASH co